NEW DELHI: Soaring demand for weight-loss therapies has brought Eli Lilly's Mounjaro within striking distance of Indian pharma market's long standing market leader GlaxoSmithKline's Augmentin, an antibiotic. During September, Mounjaro recorded sales of Rs 80 crore, becoming the second-largest brand in the pharma retail market, latest data culled by TOI from market research firm Pharmatrac showed. As against this, Augmentin generated sales of Rs 85 crore during the month. Typically, top-selling medicines in the pharmaceutical market are either Augmentin or anti-diabetic therapy, Mixtard, which generates around Rs 75-80 crore in monthly sales. Launched in March this year, Mounjaro generated a cumulative revenue of Rs 233 crore by September.

Augmentin unit value lower than Mounjaro’s

See Full Page